Abstract Acute rhinosinusitis (ARS) is defined as an inflammation of the mucosa of the nose and paranasal sinuses and affects 1-5 % of general population in Europe. Sinonasal diseases represent the main cause of smell alterations in adult patients and lead to mucosal congestion, increased quantity and density of secretions and altered mucociliary transport. For this reason the odorous molecules contained in the inspired air, cannot interact with the olfactory epithelium. Medical therapy of ARS has to reduce the severity and duration of symptoms and prevent complications. Recent studies have shown that Sodium hyaluronate modulate inflammation and has a reparative effect on the nasal mucosa. 48 patients affected by acute rhinosinusitis proven by CT scan, were enrolled. They were submitted to nasal endoscopy, olfactometric and mucociliary transport evaluation (MCTt), Visual Analogue Scale Questionnaire (VAS) at T0, after 14-18 days (T1) and after 30-35 days (T2). The patients were randomized into two treatment groups, A and B, and were treated for 30 days; each group was composed of 24 subjects. All patients received Levofloxacin (500 mg for 10 days) and Prednisone (50 mg for 8 days, 25 mg for 4 days and 12, 5 mg for 4 days). Moreover, Group A received twice a day for 30 days high molecular weight Sodium Hyaluronate (3 %) plus saline solution (3 mL sodium chloride-NaCl-0.9 %) using a nebulizer ampoule for nasal douche. Group B received twice a day for 30 days saline solution (6 mL sodium chloride-NaCl-0.9 %) using a nebulizer ampoule for nasal douche. At T1 Group A shown lower values in MCTt and threshold score was significantly higher than in Group B. VAS showed statistically significant differences between the two groups, in particular for smell, nasal obstruction and for nasal discharge. At T2 Group A MCTt was significantly lower than in Group B; odour threshold improved in both groups but in Group A was still significantly higher than in Group B. No statistical differences between two groups regarding odour discrimination and odour identification were confirmed at T1 and T2. VASy score showed statistically significant differences between the two groups only for nasal discharge.
Introduction
Acute rhinosinusitis (ARS) is defined as an inflammation of the mucosa of the nose and paranasal sinuses characterized by two or more of these symptoms: nasal congestion, nasal discharge or post-nasal drip, facial pain or pressure, loss or reduction of smell. Additional symptoms such as headache or fever may occur [1] .
ARS affects 1-5 % of general population in Europe; it has a substantial socio-economic impact and the recurring form may have a negative impact on quality of life [2] . Sinonasal diseases represent the main cause of smell alterations in adult patients [3] . Inflammation of the sinonasal mucosa leads to mucosal congestion, increased quantity and density of secretions and altered mucociliary transport. In this condition, the odorous molecules contained in the inspired air, cannot interact with the olfactory epithelium due to alterations of the conductive mechanism but also to local inflammation, which impedes the arrival of odorants to the receptors of the cilia [4] . The primary goal of medical therapy of ARS is to reduce the severity and duration of symptoms and prevent complications.
In the last few years, intranasal sodium hyaluronate is being used more often in the treatment of chronic sinonasal diseases [5] [6] [7] . Sodium hyaluronate has a reparative effect on the nasal mucosa; it modulates mucosal inflammation and increases mucociliary clearance even after nasal and sinus surgery. This results in an overall restoration of the tissue elasticity and of the epithelial physiological functions [8, 9] . This is the first comparative study performed to assess eventual deficits of smell conduction in 2 group of patients suffering from acute bacterial rhinosinusitis, receiving treatment with systemic antibiotics and steroids as well as coadjuvant treatment with high molecular weight intranasal sodium hyaluronate in one group and saline solution in the other.
Material and method
In this study, we enrolled 48 consecutive patients who came to our attention at the Rhino-Allergology clinic, Department of Sense Organs of Sapienza University, from December 2014 to April 2015.
All patients were thoroughly informed about the study and they signed an informed consent.
All patients presented one episode of acute bacterial rhinosinusitis symptoms according to the EPOS guidelines (T0) and they underwent according to the design of the study:
• Anamnesis;
• ENT examination with nasal endoscopy using by a 2.7 mm 0°rigid endoscope; • Visual Analog Scale (VAS) Questionnaire for subjective assessment of symptoms: nasal obstruction, nasal discharge, post-nasal drip, facial pain (0 = absent; 1 = mild; 2 = moderate; 3 = severe) and olfactory perception (0 = normal; 1 = decreased; 2 = absent); • Olfactometric examination by Sniffin' Sticks method (Bughart, Wedel, Germany). During the test the patient was asked to smell penn-like devices that are filled with odorant and divided into three series; The first series comprises 16 ascending concentration of n-butanolo and permits the assessment of the threshold (T); the second series features two identical substances and one different substance to asses discrimination (D) and the third series consist of 16 odours of common substances to asses identification (I). A score between 0 and 16 is given for each of the three subtests. [10] .
• Nasal MCTt determination using some charcoal powder placed on the head of the inferior turbinate and evaluating the moment in which a blackish colouring appears in the oro-pharynx (normal values = 12 ± 3 min);
• CT scan of nasal and sinusal structures with axial, coronal and sagittal projections to exclude nasal polyposis conditions.
ENT examination with nasal endoscopy, VAS questionnaire and olfactometric evaluations were performed after 14-18 days (T1) and after 30-35 days (T2).
The patients were randomized into two treatment groups, A and B, and were treated for 30 days; each group was composed of 24 subjects. All patients received antibiotic and steroid systemic therapy consisting of Levofloxacin (500 mg for 10 days) and Prednisone (50 mg for 8 days, 25 mg for 4 days and 12, 5 mg for 4 days). Moreover, Group A received twice a day for 30 days high molecular weight (800,000-1,000,000 Daltons) Sodium Hyaluronate (3 %) plus saline solution (3 mL sodium chloride-NaCl-0.9 %) using a nebulizer ampoule for nasal douche (Rinowash, Air Liquide Medical System Spa). Group B received twice a day for 30 days saline solution (6 mL sodium chloride-NaCl-0.9 %) using a nebulizer ampoule for nasal douche (Rinowash, Air Liquide Medical System Spa).
Statistical analysis was performed by comparing the data of the two groups of treatment at T0, T1 and T2. Chisquare test was used for categorical variables and nonparametric Wilcoxon Mann-Whitney test was used for continuous variable. Continuous variables were presented as median and interquartile range (IQR). All data were analysed using Stata SE 10.1 System.
Results
We enrolled 48 patients divided into two groups. Group A was composed of 24 patients, 12 male and 12 female, mean age of 44 years (38-50 IQR); Group B was composed of 24 patients, 14 male and 10 female, mean age of 43 years (35-55 IQR). All patients enrolled in the study completed all evaluations and no episodes of drug intolerance occurred.
CT results shown rhinosinusitis with congestion on osteo-meatal complex in 100 % of patients. Rhinosinusitis involved ethmoidal sinus, both ethmoidal and maxillar sinuses, both ethmoidal and frontal sinuses, in 15, 65 and 20 % of cases, respectively, in Group A and in 25, 45 and 30 %, respectively, in Group B. Table 1 shows the baseline characteristics of the patients making up the two groups: there were no statistical differences between the two groups in demographic, olfactometric data (threshold, discrimination, and identification) and MCT time.
The self-assessment questionnaires (VAS) score showed statistically significant differences between the two groups regarding nasal discharge (p = 0.010) and post-nasal drip (p = 0.02) ( Table 1) . Table 2 shows T1 results after 14-18 days' treatment. In Group A MCTt was significantly lower than in Group B: the median value was 15 min (IQR: 12.5-15) in Group A and 20 min (IQR: [15] [16] [17] [18] [19] [20] in Group B (p = 0.003).
In Group A odour threshold was significantly higher than in Group B: median threshold score was 8 (IQR: 5-8.5) in Group A and 5.5 (IQR: 4-7) in Group B (p = 0.042). There were no statistical differences between the two groups regarding odour discrimination and odour identification.
The replies to the self-assessment questionnaires (VAS) showed statistically significant differences between the two groups, in particular for smell (p = 0.018), nasal obstruction (p \ 0.001) and for nasal discharge (p = 0.006) ( Table 2) . Table 3 shows T2 results after 30 days treatment. In Group A MCTt was significantly lower than in Group B: the median value was 15 min in both groups but there was a different distribution of values (IQR: 10-15 in Group A, IQR: 15-15 in Group B) (p = 0.021). Odour threshold improved in both groups but in Group A was still significantly higher than in Group B: median threshold score was 10 (IQR: 8-11) in Group A and 8 (IQR: 7.5-9) in Group B (p = 0.007). No statistical differences between two groups regarding odour discrimination and odour identification were confirmed.
The self-assessment questionnaires (VAS) score showed statistically significant differences between the two groups only for nasal discharge (p = 0.040, same median, different distribution) ( Table 3) .
Discussion
Via the olfactory neuroepithelium and the central nervous system processes, humans are able to recognize and discriminate many different odorant molecules. The interaction of odorants to a specific binding receptor protein in the cilia of olfactory neuroepithelium represents the first step in the identification and detection of chemically distinct odorants.
There are many causes of olfactory dysfunction; in many cases it is determined by inflammation of the upper respiratory tract and the rhinosinus diseases [11, 12] . Several studies have reported different aetiological factors in patients with smell disorders. As reported by Keller and Malasapina, sinonasal etiology has been reported in a percentage ranging from 14 to 48 %, according to different case studies [13] . In our previous study conducted in 2006 , rhinosinusal pathologies were the aetiopathological factor indentified in 6.3 % of 243 patients reporting olfactory dysfunction [14] .
In acute rhinosinusitis, the irritative-inflammatory state may determine reduction or loss of smell by means dual mechanism of action. First, mucosal edema and congestion, and the alteration of quantity and density of the nasal secretions, cause a mechanical conduction block of odorous substances that can no longer interact with the binding receptor. Furthermore, the local edema and the products of inflammation may damage the primary olfactory neuron and could inhibit the transmission of synaptic impulses [4] . In some studies, it was observed that the severity of olfactory loss depends on degree and duration of these inflammatory changes [15] . Even if many pathophysiological mechanisms of smell dysfunction were thoroughly investigated, clinical and therapeutic options are still limited.
Considering the real incidence of acute rhinosinusitis, we can understand the real impact that the alteration of smell can have on quality of life.
Sodium hyaluronate, a high molecular weight non-sulphated glycosaminoglycan, is the major component in most organs and tissue and it has many functions. It is the principal component of the extracellular matrices of the respiratory epithelial cells and gland serous cells in the mucosa of upper airways and tracheobronchial tracts. Sodium hyaluronate promotes tissue proliferation and tissue remodelling and modulates cell migration and chemotaxis, angiogenesis and inflammatory responses [16, 17] . Inflammatory factors, as free radicals and enzymes, lead to a fragmentation of hyaluronic acid and the low molecular weight molecules which are formed, act as proinflammatory mediators, promoting and supporting the immune response. For this reason, the presence of high molecular weight of hyaluronic acid suppresses immune system function and limits the inflammatory response [9, 18] . Furthermore, on the nasal mucosa sodium hyaluronate can increase mucociliary activity and regulates vasomotor tone and serous and mucous gland secretion [19, 20] .
In the last few years, some authors have conducted clinical studies to evaluate the effect of sodium hyaluronate on the nasal mucosa. Forteza et al. demonstrated that sodium hyaluronate stimulates ciliary clearance of foreign material HA and regulates the activity of the enzymes, which are essential for maintaining the homeostasis at the apical surface [21] . Numerous studies have evaluated the role of sodium hyaluronate in the prevention of exacerbations of chronic rhinosinusitis and in the postoperative tissue repair after sinonasal surgery, contributing to the regeneration of the nasal mucosa and promoting post-infection and post-operative remodelling actions [6] [7] [8] [22] [23] [24] .
In our study, we investigated the effects of sodium hyaluronate in the treatment of acute rhinosinusitis. In Group A we added, Sodium Hyaluronate (3 %) plus saline solution (3 mL-NaCl-0.9 %) to antibiotic and steroid therapy using a nebulizer ampoule for nasal douche and we evaluated the patients enrolled after 14 (T1) and 30 (T2) days' therapy. All patients underwent MCT time evaluation, an olfactometric examination by Sniffin' Sticks method for evaluation of odour threshold, odour discrimination and odour identification, and they filled out a VAS questionnaire for subjective assessment of nasal obstruction, nasal discharge, post-nasal drip, facial pain and olfactory perception.
During the first evaluation (T0), there were no statistical differences among olfactory parameters. At the first clinical control (T1), we have found that in Group A odour threshold was significantly higher than in Group B. At the second control (T2), odour threshold had improved both in Group A and in the Group B, but the values were better in Group A. There were no statistical differences between the two groups regarding odour discrimination and odour identification at T1 and T2 controls.
The evaluation of MCTt showed that after just 14 days therapy (T1) the values were in accordance with the standard limits in Group A.
The data of subjective assessment of symptoms showed that at T0 the nasal discharge and post-nasal drip scores were worse in Group A than in Group B. Nevertheless, the subjective data related to smell, nasal obstruction and nasal discharge at the first control (T1) were better in Group A than in Group B, and at the second control (T2) the only statistical difference between the two groups regarded nasal discharge.
Thus, our data show that sodium hyaluronate administered as adjuvant treatment, has improved odour threshold, TMCt and subjective symptoms in Group A after 14 days of therapy. The modulation of inflammation and the reparative action in the nasal mucosa and in the olfactory epithelium, as well as better mucociliary clearance, have favoured a reduction of mucosal inflammation and interaction between odorous molecules and olfactory epithelium. After 30 days of therapy, there were no differences between the two groups, except for the nasal discharge symptom. Therefore, as shown by our data, the effects of sodium hyaluronate in the treatment of acute rhinosinusitis could facilitate fasten physiological recovery of the nasal functions, reducing the severity and duration of symptoms.
Conclusion
Olfaction is a critical physiological process of the nasal airway that is related to a number of health and social factors that are crucial for quality of life. Considering the incidence of rhinosinusitis throughout the world and the social costs associated with this condition, the search for a drug that reduces the severity and duration of symptoms becomes essential.
Therefore, several studies have demonstrated that sodium hyaluronate might be a valuable option in the management of chronic rhinosinusitis and in its post-operative treatment. Our study shows that sodium hyaluronate may also play an important role in the treatment of acute rhinosinusitis favouring tissutal repair, restoring mucosal function and reducing both the severity and duration of symptoms.
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